Cherevka Holli 4
4 · Ampio Pharmaceuticals, Inc. · Filed Oct 2, 2018
Insider Transaction Report
Form 4
Cherevka Holli
Chief Operating Officer
Transactions
- Disposition to Issuer
Employee Stock Option (Right to Buy)
2018-10-01−45,000→ 0 totalExercise: $4.72Exp: 2023-04-02→ Common Stock (45,000 underlying) - Award
Employee Stock Option (Right to Buy)
2018-10-01+30,000→ 30,000 totalExercise: $0.75Exp: 2024-10-06→ Common Stock (30,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2018-10-01−170,000→ 0 totalExercise: $1.03Exp: 2026-07-15→ Common Stock (170,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2018-10-01−35,000→ 0 totalExercise: $4.16Exp: 2023-01-14→ Common Stock (35,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2018-10-01−9,402→ 0 totalExercise: $8.62Exp: 2023-11-08→ Common Stock (9,402 underlying) - Award
Employee Stock Option (Right to Buy)
2018-10-01+9,402→ 9,402 totalExercise: $0.75Exp: 2023-11-08→ Common Stock (9,402 underlying) - Award
Employee Stock Option (Right to Buy)
2018-10-01+45,000→ 45,000 totalExercise: $0.75Exp: 2023-04-02→ Common Stock (45,000 underlying) - Disposition to Issuer
Employee Stock Option (Right to Buy)
2018-10-01−30,000→ 0 totalExercise: $3.43Exp: 2024-10-06→ Common Stock (30,000 underlying) - Award
Employee Stock Option (Right to Buy)
2018-10-01+170,000→ 170,000 totalExercise: $0.75Exp: 2026-07-15→ Common Stock (170,000 underlying) - Award
Employee Stock Option (Right to Buy)
2018-10-01+35,000→ 35,000 totalExercise: $0.75Exp: 2023-01-14→ Common Stock (35,000 underlying)
Footnotes (2)
- [F1]The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") that became effective on October 1, 2018 and are being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934. Pursuant to the Option Repricing, the exercise price of each "Relevant Option" has been amended to reduce such exercise price to $0.75. There have been no other changes to the terms of the Relevant Options.
- [F2]The stock options have vested and have become fully exercisable.